Varenicline and cardiovascular adverse events: A perspective review

Therapeutic Advances in Drug Safety

Volumn 5, Issue 4, 2014, Pages 167-172

  Chelladurai, Yohalakshmi ^a   Singh, Sonal ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

adverse events; cardiovascular; Champix; Chantix; review; varenicline

Indexed keywords

PLACEBO; VARENICLINE;

ATTRIBUTABLE RISK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; FOOD AND DRUG ADMINISTRATION; HEART INFARCTION; HUMAN; PATIENT EDUCATION; PATIENT MONITORING; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; SMOKING CESSATION; SYSTEMATIC REVIEW; TREATMENT DURATION; UNSTABLE ANGINA PECTORIS;

EID: 84903530709     PISSN: 20420986     EISSN: 20420994     Source Type: Journal    
DOI: 10.1177/2042098614530421     Document Type: Review

References (17)

1. Cahill K. Stevens S. Perera R. Lancaster T. (2013) Pharmacological interventions for smoking cessation: an overview and network meta-analysis. Cochrane Database Syst Rev 5: CD009329.
2. Critchley J. Capewell S. (2003) Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: a systematic review. JAMA 290: 86–97.
3. Critchley J. Capewell S. (2004) Smoking cessation for the secondary prevention of coronary heart disease. Cochrane Database Syst Rev: CD003041.
4. Fagerstrom K. Hughes J. (2008) Varenicline in the treatment of tobacco dependence. Neuropsychiatr Dis Treat 4: 353–363.
5. Keus F. Wetterslev J. Gluud C. Gooszen H. Van Laarhoven C. (2009) Robustness assessments are needed to reduce bias in meta-analyses that include zero-event randomized trials. Am J Gastroenterol 104: 546–551.
6. Mills E. Wu P. Lockhart I. Thorlund K. Puhan M. Ebbert J. (2012) Comparisons of high-dose and combination nicotine replacement therapy, varenicline, and bupropion for smoking cessation: a systematic review and multiple treatment meta-analysis. Ann Med 44: 588–597.
7. Pfizer, Inc. (2006) Supervisory review of NDA safety review and primary clinical efficacy review varnecline. Pfizer, Inc., Vol. 2013. New York: Pfizer, Inc.
8. Pfizer, Inc. (2010) Highlights of Prescribing Information – Chantix (varenicline) tablets. New York: Pfizer, Inc.
9. Pfizer, Inc. (2011) Highlights of Prescribing Information – Chantix (varenicline) tablets. New York: Pfizer, Inc.
10. Pfizer, Inc. (2013) Highlights of Prescribing Information – Chantix (varenicline) tablets. New York: Pfizer, Inc.
11. Prochaska J. Hilton J. (2012) Risk of cardiovascular serious adverse events associated with varenicline use for tobacco cessation: systematic review and meta-analysis. BMJ 344: e2856.
12. Rigotti N. Pipe A. Benowitz N. Arteaga C. Garza D. Tonstad S. (2010) Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial. Circulation 121: 221–229.
13. Rollema H. Chambers L. Coe J. Glowa J. Hurst R. Lebel L. (2007) Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid. Neuropharmacology 52: 985–994.
14. Singh S. Loke Y. Spangler J. Furberg C. (2011) Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis. CMAJ 183: 1359–1366.
15. US Public Health Service (2008) Treating tobacco use and dependence: 2008 update. US Public Health Service Clinical Practice Guideline executive summary. Respir Care 53: 1217–1222.
16. US Surgeon General (2004) The Health Consequences of Smoking: A Report of the Surgeon General. Atlanta, GA: US Department of Health and Human Services.
17. Ware J. Vetrovec G. Miller A. Van Tosh A. Gaffney M. Yunis C. (2013) Cardiovascular safety of varenicline: patient-level meta-analysis of randomized, blinded, placebo-controlled trials. Am J Ther 20: 235–246.